Austin Institute for Clinical Research
Welcome,         Profile    Billing    Logout  
 15 Trials 
31 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldberg, David
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Completed
3
86
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
PLATyPuS, NCT02315898: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

Completed
2
40
US
Treatment-inhaled tPA, alteplase, Activase
University of Michigan, Genentech, Inc.
Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
03/21
06/23
NCT04844840: A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Completed
2
29
US
STP705, STP705 Powder for Injection, Placebo
Sirnaomics
Keloid
05/23
05/23
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Active, not recruiting
2
201
US
Epclusa
University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease
06/25
01/26
FALD, NCT03430583: Evaluation of Fontan-Associated Liver Disease

Completed
N/A
88
Canada, US
MZ101
Mezzion Pharma Co. Ltd, National Heart, Lung, and Blood Institute (NHLBI)
Single Ventricle Heart Disease
09/20
09/20
NCT05358860: Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Completed
N/A
60
US
Sofwave, SUPERB
Sofwave Medical LTD
Acne Scars - Mixed Atrophic and Hypertrophic
12/22
12/22
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator

Completed
N/A
60
US
Sofwave
Sofwave Medical LTD
Cellulite
11/23
11/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/25
12/25
Rich, Phoebe
NCT06857942: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Recruiting
4
200
US
Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Overweight or Obesity
10/26
10/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
NCT05135910: To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

Active, not recruiting
2a
35
US
Hallux Terbinafine Subungual Gel, HSG
Hallux, Inc.
Onychomycosis of Toenail
09/24
09/24
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia

Completed
2
71
US
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Technoderma Medicines Inc., Therapeutics, Inc.
Alopecia, Androgenetic
11/23
01/24
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Recruiting
2
60
US
SM-020 gel 1.0%, Vehicle gel
DermBiont, Inc.
Seborrheic Keratosis
09/24
10/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Couvillion, Megan P
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Active, not recruiting
3
172
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
08/25
05/26
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
Schleicher, Stephen
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Completed
2
82
US
TLL018 tablets, TLL018 Placeboes
Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
12/24
12/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Thibeaux, J'dah
ASCEND, NCT05295732: The Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed
3
209
Europe, Canada, US
TMB-001, Matching Vehicle
Timber Pharmaceuticals Inc., LEO Pharma
Ichthyosis
06/24
09/24
Doctoroff, Alexander
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Yuengel-Bienenfeld, Christine
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldberg, David
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Completed
3
86
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
PLATyPuS, NCT02315898: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

Completed
2
40
US
Treatment-inhaled tPA, alteplase, Activase
University of Michigan, Genentech, Inc.
Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
03/21
06/23
NCT04844840: A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Completed
2
29
US
STP705, STP705 Powder for Injection, Placebo
Sirnaomics
Keloid
05/23
05/23
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Active, not recruiting
2
201
US
Epclusa
University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease
06/25
01/26
FALD, NCT03430583: Evaluation of Fontan-Associated Liver Disease

Completed
N/A
88
Canada, US
MZ101
Mezzion Pharma Co. Ltd, National Heart, Lung, and Blood Institute (NHLBI)
Single Ventricle Heart Disease
09/20
09/20
NCT05358860: Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Completed
N/A
60
US
Sofwave, SUPERB
Sofwave Medical LTD
Acne Scars - Mixed Atrophic and Hypertrophic
12/22
12/22
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator

Completed
N/A
60
US
Sofwave
Sofwave Medical LTD
Cellulite
11/23
11/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/25
12/25
Rich, Phoebe
NCT06857942: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Recruiting
4
200
US
Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Overweight or Obesity
10/26
10/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
NCT05135910: To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

Active, not recruiting
2a
35
US
Hallux Terbinafine Subungual Gel, HSG
Hallux, Inc.
Onychomycosis of Toenail
09/24
09/24
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia

Completed
2
71
US
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Technoderma Medicines Inc., Therapeutics, Inc.
Alopecia, Androgenetic
11/23
01/24
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Recruiting
2
60
US
SM-020 gel 1.0%, Vehicle gel
DermBiont, Inc.
Seborrheic Keratosis
09/24
10/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Couvillion, Megan P
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Active, not recruiting
3
172
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
08/25
05/26
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
Schleicher, Stephen
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Completed
2
82
US
TLL018 tablets, TLL018 Placeboes
Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
12/24
12/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Thibeaux, J'dah
ASCEND, NCT05295732: The Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed
3
209
Europe, Canada, US
TMB-001, Matching Vehicle
Timber Pharmaceuticals Inc., LEO Pharma
Ichthyosis
06/24
09/24
Doctoroff, Alexander
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Yuengel-Bienenfeld, Christine
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25

Download Options